Syngene International share price gained in the early trade on June 16 following zero observations from the United States Food and Drug Administration (USFDA) to Bengaluru facility.
At 09:22am, Syngene International was quoting at Rs 657.80, up Rs 5.30, or 0.81 percent, on the BSE.
"The United States Food and Drug Administration (USFDA) conducted a Good Clinical Practices (GCP) compliance inspection of Syngene International's facility at Semicon
Park, Bengaluru, from June 09 to June 13, 2025," company said.
The inspection concluded successfully, with the facility found to be in compliance with the required regulations.
The inspection resulted in zero observations and no Form 483 was issued. The inspection has been classified as No Action Indicated (NAI), it added.
Catch all the market action on our live blogLast week the company received Establishment Inspection Report (EIR) from USFDA after the routine current Good Manufacturing Practices (cGMP) inspection at GMP manufacturing facilities located at Biocon Park, SEZ, Bengaluru from February 10 to 20, 2025. The EIR concluded the inspectional outcome as Voluntary Action Indicated (VAI).
The share touched a 52-week high of Rs 960.00 and a 52-week low of Rs 598.55 on 02 December, 2024 and 09 May, 2025, respectively.
Currently, the stock is trading 31.48 percent below its 52-week high and 9.9 percent above its 52-week low.
The market capitalisation of the company stands at Rs 26,505.36 crore.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
